Get the Stockscreener App
2.66
1.12%
-0.03
Pre-market:
3.14
0.48
+18.05%
Nrx Pharmaceuticals Inc stock is traded at $2.66, with a volume of 1.76M.
It is down -1.12% in the last 24 hours and down -8.90% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.69
Open:
$2.7
24h Volume:
1.76M
Relative Volume:
1.76
Market Cap:
$115.17M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-1.6945
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
+6.83%
1M Performance:
-8.90%
6M Performance:
-10.74%
1Y Performance:
-11.92%
1-Day Range:
$0.00
$0.00
1-Week Range:
$2.459
$2.7732
52-Week Range:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.66 | 115.17M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag Estimates - Zacks Investment Research
NRx Pharmaceuticals (NasdaqCM:NRXP) Stock Forecast & Analyst Predictions - Simply Wall Street
Total common shares outstanding of NRX Pharmaceuticals, Inc. – HAN:B1Q - TradingView
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering - Yahoo Finance
FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP) - FinancialContent
NRXP: Preservative-free ketamine and robotic TMS drive innovation, with FDA decision expected soon - TradingView
NRx Pharmaceuticals at Cantor conference: ketamine push gains momentum By Investing.com - Investing.com Canada
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - Investing News Network
NRx deploys FDA-cleared robotic TMS system in Florida - grafa.com
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System - Yahoo Finance
NRx Pharmaceuticals to Present at Three September Investor Conferences - citybiz
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Nasus Pharma Files $50 Million Shelf Registration - Yahoo Finance
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - The Ithaca Journal
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded by Zacks Research to Strong Sell - MarketBeat
VolitionRx Files for Secondary Offering of Common Shares - Yahoo Finance
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 - Investing.com
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy on NRx Pharmaceuticals stock at $45 By Investing.com - Investing.com UK
NRx Advances Ketamine Bid After FDA Review Clears Drug - MyChesCo
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - barchart.com
NRX (NRXP) Momentum: Ends Higher by 5.41% at $3.51 for the Current Session; the Current Price Sits Inside the Supplied Technical RangeIV Contraction - Vinanet
NRx cites arbitration in Kadima acquisition dispute - scanx.trade
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
Nrx Pharmaceuticals Earnings Call Signals Cautious Momentum - TipRanks
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo Finance
NRx Pharmaceuticals Targets 2026 KETAFREE Approval, Advances DARPA-Backed Depression Trial - citybiz
NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Cuts Target Price to $10 - moomoo.com
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
NRX Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NRx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Investing News Network
NRX Pharmaceuticals Q2 Results: EPS Misses Estimate, Sales Fall 94% - scanx.trade
NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand - TradingView
Five million ketamine doses are in production—but when can sales start? - Stock Titan
Press Release: NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to Be Held on Monday, August 17th at 4:30pm ET - Moomoo
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - GlobeNewswire
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET - Yahoo Finance
NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ... - Yahoo Finance
NRx Pharmaceuticals, Inc. (NRXP) reports Q2 loss, misses revenue estimates - FXStreet
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS - MarketBeat
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
NRX Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk - Stock Titan
NRX Pharmaceuticals Inc expected to post earnings of 6 cents a shareEarnings Preview - TradingView
NRXP Q2'26 Earnings: EPS estimate is (0.11) USD - TradingView
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):